首页 > 最新文献

Journal of cancer & allied specialties最新文献

英文 中文
Does Tumor Grade Have any Prognostic Significance in Chromophobe Renal Cell Carcinoma: A Clinicopathological Study. 憎色性肾细胞癌的肿瘤分级是否有预后意义:一项临床病理研究。
Pub Date : 2026-03-12 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0009
Shariqah Sadaf, Sajid Mushtaq, Madiha Syed, Usman Hassan, Mudassar Hussain, Asif Loya, Maryam Hameed, Umer Nisar Sheikh

Introduction: Chromophobe renal cell carcinoma (CHRCC) is the third most common RCC subtype, typically with a favorable prognosis, though some cases show aggressive behavior. The prognostic utility of tumor grading in CHRCC remains controversial, particularly regarding the Fuhrman grading system due to inherent nuclear atypia. The Paner et al. three-tiered chromophobe tumor grading (CTG) system addresses these limitations by incorporating nuclear crowding and anaplasia. This study evaluates CTG's prognostic value versus Fuhrman grading and other factors like pT stage, sarcomatoid differentiation, and tumor necrosis.

Materials and methods: This retrospective study analyzed 51 patients who underwent radical nephrectomy for chromophobe renal cell carcinoma (CHRCC) at Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, between 2014 and 2019. Tumors were graded using the Fuhrman and Paner CTG systems. Prognostic factors assessed included pT stage, sarcomatoid differentiation, and tumor necrosis. Statistical analysis used Chi-square and independent sample T-tests. Survival analysis was performed using Kaplan-Meier curves to determine overall survival (OS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS).

Results: Most cases (68.6%) were CTG grade 1-2, and 31.4% were grade 3. All adverse events occurred in grade 3 tumors (DMFS 75%, RFS 93.8%, CSS 87.5%). Grades 1-2 had 100% survival. Fuhrman grading showed less prognostic relevance due to inconsistent results. Tumor necrosis and advanced pT stage correlated with poor outcomes. Sarcomatoid differentiation appeared in one of four progressing cases.

Conclusion: The Paner CTG system effectively stratifies CHRCC patients by prognostic risk. It outperforms Fuhrman grading in predicting adverse outcomes. Higher tumor grade, necrosis, and advanced pT stage all significantly correlated with poor prognosis. These findings support adopting the Paner grading system for CHRCC to improve risk stratification and clinical decisions. Larger studies are warranted to validate these results.

憎色性肾细胞癌(CHRCC)是第三种最常见的肾细胞癌亚型,通常预后良好,尽管一些病例表现出侵袭性行为。在CHRCC中,肿瘤分级的预后效用仍然存在争议,特别是由于固有的核非典型性,关于Fuhrman分级系统。Paner等人的三层憎色肿瘤分级(CTG)系统通过纳入核拥挤和发育不全解决了这些局限性。本研究比较CTG与Fuhrman分级及其他因素(如pT分期、肉瘤样分化和肿瘤坏死)的预后价值。材料和方法:本回顾性研究分析了2014年至2019年在拉合尔Shaukat Khanum纪念癌症医院和研究中心接受根治性肾切除术治疗恐色肾细胞癌(CHRCC)的51例患者。采用Fuhrman和Paner CTG系统对肿瘤进行分级。评估的预后因素包括pT分期、肉瘤样分化和肿瘤坏死。统计分析采用卡方检验和独立样本t检验。采用Kaplan-Meier曲线进行生存分析,确定总生存期(OS)、无复发生存期(RFS)和远端无转移生存期(DMFS)。结果:CTG 1 ~ 2级占68.6%,3级占31.4%。所有不良事件均发生在3级肿瘤中(DMFS 75%, RFS 93.8%, CSS 87.5%)。1-2年级的存活率为100%。由于结果不一致,福尔曼分级显示预后相关性较小。肿瘤坏死和晚期pT与预后不良相关。4例进展病例中有1例出现肉瘤样分化。结论:Paner CTG系统根据预后风险对CHRCC患者进行了有效的分层。它在预测不良后果方面优于福尔曼评分法。肿瘤分级高、坏死、pT分期晚期均与预后不良显著相关。这些发现支持采用Paner分级系统来改善CHRCC的风险分层和临床决策。需要更大规模的研究来验证这些结果。
{"title":"Does Tumor Grade Have any Prognostic Significance in Chromophobe Renal Cell Carcinoma: A Clinicopathological Study.","authors":"Shariqah Sadaf, Sajid Mushtaq, Madiha Syed, Usman Hassan, Mudassar Hussain, Asif Loya, Maryam Hameed, Umer Nisar Sheikh","doi":"10.2478/jcas-2025-0009","DOIUrl":"https://doi.org/10.2478/jcas-2025-0009","url":null,"abstract":"<p><strong>Introduction: </strong>Chromophobe renal cell carcinoma (CHRCC) is the third most common RCC subtype, typically with a favorable prognosis, though some cases show aggressive behavior. The prognostic utility of tumor grading in CHRCC remains controversial, particularly regarding the Fuhrman grading system due to inherent nuclear atypia. The Paner et al. three-tiered chromophobe tumor grading (CTG) system addresses these limitations by incorporating nuclear crowding and anaplasia. This study evaluates CTG's prognostic value versus Fuhrman grading and other factors like pT stage, sarcomatoid differentiation, and tumor necrosis.</p><p><strong>Materials and methods: </strong>This retrospective study analyzed 51 patients who underwent radical nephrectomy for chromophobe renal cell carcinoma (CHRCC) at Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, between 2014 and 2019. Tumors were graded using the Fuhrman and Paner CTG systems. Prognostic factors assessed included pT stage, sarcomatoid differentiation, and tumor necrosis. Statistical analysis used Chi-square and independent sample T-tests. Survival analysis was performed using Kaplan-Meier curves to determine overall survival (OS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS).</p><p><strong>Results: </strong>Most cases (68.6%) were CTG grade 1-2, and 31.4% were grade 3. All adverse events occurred in grade 3 tumors (DMFS 75%, RFS 93.8%, CSS 87.5%). Grades 1-2 had 100% survival. Fuhrman grading showed less prognostic relevance due to inconsistent results. Tumor necrosis and advanced pT stage correlated with poor outcomes. Sarcomatoid differentiation appeared in one of four progressing cases.</p><p><strong>Conclusion: </strong>The Paner CTG system effectively stratifies CHRCC patients by prognostic risk. It outperforms Fuhrman grading in predicting adverse outcomes. Higher tumor grade, necrosis, and advanced pT stage all significantly correlated with poor prognosis. These findings support adopting the Paner grading system for CHRCC to improve risk stratification and clinical decisions. Larger studies are warranted to validate these results.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"51-61"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Periampullary adenoma leading to duodenojejunal intussusception in a young woman: A case report. 壶腹周围腺瘤导致十二指肠空肠肠套叠1例。
Pub Date : 2026-03-12 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0010
Abu Bakar Bhatti, Usman Shafique Khokhar, Hajira Ghairat

Background: Duodenojejunal intussusception (DJI) is an uncommon clinical entity in adults, most often secondary to an underlying structural lesion. Its nonspecific gastrointestinal symptoms and rarity frequently delay diagnosis and complicate management.

Case description: We present the case of a 30-year-old woman with an 18-month history of right hypochondrial pain, intermittent non-bilious vomiting, and significant weight loss. Imaging and endoscopic biopsy revealed duodenojejunal intussusception secondary to a large periampullary tubulovillous adenoma. Although a transduodenal ampullectomy was initially planned, the procedure was converted to a pancreaticoduodenectomy due to the lesion's size and morphology. The postoperative course was uneventful, and the patient has remained asymptomatic and in good health for more than fifteen months after surgery.

Practical implications: DJI secondary to periampullary adenoma is rare but clinically significant. While endoscopic or limited surgical resection may be appropriate in select cases, pancreaticoduodenectomy offers a definitive treatment option when ampullectomy is not feasible.

背景:十二指肠空肠肠套叠(DJI)在成人中是一种罕见的临床疾病,通常继发于潜在的结构性病变。其非特异性胃肠道症状和罕见性往往延误诊断和复杂的治疗。病例描述:我们报告一名30岁的女性,有18个月的右肋软骨疼痛史,间歇性非胆汁性呕吐,体重明显下降。影像学和内镜活检显示十二指肠空肠肠套叠继发于一个大壶腹周围管状绒毛腺瘤。虽然最初计划进行经十二指肠壶胃切除术,但由于病变的大小和形态,该手术转为胰十二指肠切除术。术后过程平淡无奇,患者在术后15个多月保持无症状和健康状况良好。实际意义:继发于壶腹周围腺瘤的大疆是罕见的,但具有临床意义。虽然内镜或有限的手术切除在某些情况下是合适的,但当壶胃切除术不可行的时候,胰十二指肠切除术是一个明确的治疗选择。
{"title":"Periampullary adenoma leading to duodenojejunal intussusception in a young woman: A case report.","authors":"Abu Bakar Bhatti, Usman Shafique Khokhar, Hajira Ghairat","doi":"10.2478/jcas-2025-0010","DOIUrl":"https://doi.org/10.2478/jcas-2025-0010","url":null,"abstract":"<p><strong>Background: </strong>Duodenojejunal intussusception (DJI) is an uncommon clinical entity in adults, most often secondary to an underlying structural lesion. Its nonspecific gastrointestinal symptoms and rarity frequently delay diagnosis and complicate management.</p><p><strong>Case description: </strong>We present the case of a 30-year-old woman with an 18-month history of right hypochondrial pain, intermittent non-bilious vomiting, and significant weight loss. Imaging and endoscopic biopsy revealed duodenojejunal intussusception secondary to a large periampullary tubulovillous adenoma. Although a transduodenal ampullectomy was initially planned, the procedure was converted to a pancreaticoduodenectomy due to the lesion's size and morphology. The postoperative course was uneventful, and the patient has remained asymptomatic and in good health for more than fifteen months after surgery.</p><p><strong>Practical implications: </strong>DJI secondary to periampullary adenoma is rare but clinically significant. While endoscopic or limited surgical resection may be appropriate in select cases, pancreaticoduodenectomy offers a definitive treatment option when ampullectomy is not feasible.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"63-66"},"PeriodicalIF":0.0,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Presentation of Metastatic Colorectal Carcinoma at a Tertiary Care Center in Pakistan. 转移性结直肠癌在巴基斯坦三级保健中心的表现。
Pub Date : 2025-10-17 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0008
Sehar Salim Virani, Muhammad Taha Nasim, Fiza Adnan, Muhammad Ibrahim, Munira Shabbir Moosajee, Muhammad Rizwan Khan, Kulsoom Ghias, Muhammad Murtaza, Sadaf Khan, Syed Nabeel Zafar

Introduction: Metastatic colorectal cancer (mCRC) poses significant challenges in low- and middle-income countries (LMICs) due to limited access to comprehensive care. This study aims to analyze the clinical characteristics, treatment patterns, and outcomes of patients with metastatic colorectal cancer (mCRC) at a single tertiary care center in Pakistan.

Materials and methods: A retrospective cross-sectional study was conducted on 141 patients diagnosed with mCRC at the Aga Khan University Hospital (AKUH) between January 2020 and December 2022. Data on demographics, tumor characteristics, metastasis patterns, treatment modalities, and outcomes were extracted from electronic medical records. Descriptive statistics and survival analysis were performed.

Results: The mean age of the cohort was 51 years (SD ± 17.43), with 56.7% male patients. The study included patients from all over Pakistan, with the majority residing in Sindh (71.1%). Additionally, 8.5% of patients were from outside Pakistan. Rectum (27.5%) and sigmoid colon (20.4%) were the predominant tumor locations. Adenocarcinoma was the most common histological type (90.1%). Liver-only metastases were observed in 27.5% of patients, with 48.2% presenting multisite metastases. Chemotherapy was administered to 74.6% of patients, with FOLFOX being the most common regimen (38.3%). Primary tumor resection was performed in 43.7% of cases, and metastatic lesion resection in 7.7%. Fragmented care was observed, with 21.4% of patients receiving diagnostic or therapeutic interventions outside AKUH as well. The median time from diagnosis of metastasis to death was 4.9 months (IQR: 1.1-9.3).

Conclusion: mCRC patients in Pakistan present with a younger age, higher prevalence of multisite metastases, and limited access to advanced multimodal treatments compared to HICs. These findings underscore the need for tailored public health initiatives, including age-specific screening programs, improved diagnostic and treatment infrastructure, and enhanced access to advanced therapies to improve outcomes in LMICs.

导语:转移性结直肠癌(mCRC)在低收入和中等收入国家(LMICs)面临着巨大的挑战,因为获得综合护理的机会有限。本研究旨在分析巴基斯坦某三级医疗中心转移性结直肠癌(mCRC)患者的临床特征、治疗模式和预后。材料和方法:对2020年1月至2022年12月在阿迦汗大学医院(AKUH)诊断为mCRC的141例患者进行了回顾性横断面研究。从电子病历中提取人口统计学、肿瘤特征、转移模式、治疗方式和结果的数据。进行描述性统计和生存分析。结果:队列平均年龄51岁(SD±17.43),男性占56.7%。该研究包括来自巴基斯坦各地的患者,其中大多数居住在信德省(71.1%)。此外,8.5%的患者来自巴基斯坦以外。直肠(27.5%)和乙状结肠(20.4%)是肿瘤的主要部位。腺癌是最常见的组织学类型(90.1%)。27.5%的患者出现肝脏转移,48.2%的患者出现多部位转移。74.6%的患者接受化疗,其中FOLFOX是最常见的方案(38.3%)。原发肿瘤切除占43.7%,转移灶切除占7.7%。观察到零散的护理,21.4%的患者也接受了AKUH以外的诊断或治疗干预。从诊断转移到死亡的中位时间为4.9个月(IQR: 1.1-9.3)。结论:与hic相比,巴基斯坦的mCRC患者年龄更年轻,多部位转移患病率更高,并且获得先进的多模式治疗的机会有限。这些发现强调有必要采取有针对性的公共卫生举措,包括针对特定年龄的筛查方案,改进诊断和治疗基础设施,以及增加获得先进疗法的机会,以改善低收入和中等收入国家的结果。
{"title":"Presentation of Metastatic Colorectal Carcinoma at a Tertiary Care Center in Pakistan.","authors":"Sehar Salim Virani, Muhammad Taha Nasim, Fiza Adnan, Muhammad Ibrahim, Munira Shabbir Moosajee, Muhammad Rizwan Khan, Kulsoom Ghias, Muhammad Murtaza, Sadaf Khan, Syed Nabeel Zafar","doi":"10.2478/jcas-2025-0008","DOIUrl":"https://doi.org/10.2478/jcas-2025-0008","url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic colorectal cancer (mCRC) poses significant challenges in low- and middle-income countries (LMICs) due to limited access to comprehensive care. This study aims to analyze the clinical characteristics, treatment patterns, and outcomes of patients with metastatic colorectal cancer (mCRC) at a single tertiary care center in Pakistan.</p><p><strong>Materials and methods: </strong>A retrospective cross-sectional study was conducted on 141 patients diagnosed with mCRC at the Aga Khan University Hospital (AKUH) between January 2020 and December 2022. Data on demographics, tumor characteristics, metastasis patterns, treatment modalities, and outcomes were extracted from electronic medical records. Descriptive statistics and survival analysis were performed.</p><p><strong>Results: </strong>The mean age of the cohort was 51 years (SD ± 17.43), with 56.7% male patients. The study included patients from all over Pakistan, with the majority residing in Sindh (71.1%). Additionally, 8.5% of patients were from outside Pakistan. Rectum (27.5%) and sigmoid colon (20.4%) were the predominant tumor locations. Adenocarcinoma was the most common histological type (90.1%). Liver-only metastases were observed in 27.5% of patients, with 48.2% presenting multisite metastases. Chemotherapy was administered to 74.6% of patients, with FOLFOX being the most common regimen (38.3%). Primary tumor resection was performed in 43.7% of cases, and metastatic lesion resection in 7.7%. Fragmented care was observed, with 21.4% of patients receiving diagnostic or therapeutic interventions outside AKUH as well. The median time from diagnosis of metastasis to death was 4.9 months (IQR: 1.1-9.3).</p><p><strong>Conclusion: </strong>mCRC patients in Pakistan present with a younger age, higher prevalence of multisite metastases, and limited access to advanced multimodal treatments compared to HICs. These findings underscore the need for tailored public health initiatives, including age-specific screening programs, improved diagnostic and treatment infrastructure, and enhanced access to advanced therapies to improve outcomes in LMICs.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"40-50"},"PeriodicalIF":0.0,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12924647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Technical Feasibility and Surgical Outcomes of Laparoscopic Excision of Abdominopelvic Solid Tumors in Children: A Retrospective Review. 评估腹腔镜下儿童腹部盆腔实体瘤切除术的技术可行性和手术效果:回顾性回顾。
Pub Date : 2025-10-15 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0007
Sajid Ali, Muhammad Bilal Qayyum, Muniba Jalil, Tariq Latif, Aamir Ali Syed, Muhammad Ali Sheikh

Introduction: Minimal invasive surgery for abdominopelvic solid organ tumors in paediatric patients is a growing field. Technical challenges persist despite potential benefits, such as reduced postoperative pain and shorter recovery times.

Materials and methods: This was a retrospective review of all paediatric patients who underwent laparoscopic excision for abdominopelvic tumors. Parameters such as demographics, tumor histology, tumor location and size, blood loss, operation duration, and early outcomes were analyzed.

Results: Thirty-five patients underwent laparoscopy. The median age was 13 years. Females constituted the majority (29). Tumor sites included the pelvis (n=29), right kidney (n=2), retroperitoneal (n=3), and colon (n=1). The average tumor size was 11 cm. Successful laparoscopic excision was achieved in 32 cases, without postoperative complications, with a mean hospital stay of two days.

Conclusions: Laparoscopic excision is technically feasible for paediatric abdominopelvic solid organ tumors, offering minimal complications. However, further studies are needed to define long-term outcomes.

前言:微创手术治疗小儿腹盆腔实体器官肿瘤是一个新兴的领域。尽管有潜在的好处,如减少术后疼痛和缩短恢复时间,但技术挑战仍然存在。材料和方法:这是一项对所有接受腹腔镜手术切除腹部盆腔肿瘤的儿科患者的回顾性研究。统计学、肿瘤组织学、肿瘤位置和大小、出血量、手术时间、早期预后等参数进行分析。结果:35例患者行腹腔镜检查。平均年龄为13岁。女性占多数(29人)。肿瘤部位包括骨盆(n=29)、右肾(n=2)、腹膜后(n=3)和结肠(n=1)。肿瘤平均大小为11 cm。32例腹腔镜手术成功,无术后并发症,平均住院时间2天。结论:腹腔镜手术治疗小儿腹腔实体器官肿瘤技术可行,并发症少。然而,需要进一步的研究来确定长期结果。
{"title":"Evaluating Technical Feasibility and Surgical Outcomes of Laparoscopic Excision of Abdominopelvic Solid Tumors in Children: A Retrospective Review.","authors":"Sajid Ali, Muhammad Bilal Qayyum, Muniba Jalil, Tariq Latif, Aamir Ali Syed, Muhammad Ali Sheikh","doi":"10.2478/jcas-2025-0007","DOIUrl":"https://doi.org/10.2478/jcas-2025-0007","url":null,"abstract":"<p><strong>Introduction: </strong>Minimal invasive surgery for abdominopelvic solid organ tumors in paediatric patients is a growing field. Technical challenges persist despite potential benefits, such as reduced postoperative pain and shorter recovery times.</p><p><strong>Materials and methods: </strong>This was a retrospective review of all paediatric patients who underwent laparoscopic excision for abdominopelvic tumors. Parameters such as demographics, tumor histology, tumor location and size, blood loss, operation duration, and early outcomes were analyzed.</p><p><strong>Results: </strong>Thirty-five patients underwent laparoscopy. The median age was 13 years. Females constituted the majority (29). Tumor sites included the pelvis (n=29), right kidney (n=2), retroperitoneal (n=3), and colon (n=1). The average tumor size was 11 cm. Successful laparoscopic excision was achieved in 32 cases, without postoperative complications, with a mean hospital stay of two days.</p><p><strong>Conclusions: </strong>Laparoscopic excision is technically feasible for paediatric abdominopelvic solid organ tumors, offering minimal complications. However, further studies are needed to define long-term outcomes.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"34-39"},"PeriodicalIF":0.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12924648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast Hamartoma with Unusual Imaging Features. 具有异常影像学特征的乳腺错构瘤。
Pub Date : 2025-06-04 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0005
Palwasha Gul, Jonathan James, Mohamad Hajaj, Dima AlNajjar

Introduction: Hamartomas are benign masses seen in different organs including breasts. These are well-defined masses with a pseudocapsule and variable tissues from the surrounding organ.It is an uncommonly reported benign breast lesion, the cause and pathogenesis of its development is still not fully understood. The tumour exhibits a female predominance with a mean age of 45.

Case description: We present two cases of breast hamartoma in 51 and 61 years old female who presented to us through screening and symptomatic clinics.Both cases had imaging findings typical for diagnosis of hamartoma however there was a distortion within the hamartoma which raised possibility of malignancy and prompted a core biopsy and MDT discussion.

Practical implication: Many hamartomas have typical benign imaging appearances and require no further investigation. Biopsy is needed in atypical looking hamartomas to exclude a breast carcinoma, which although rare may develop within a hamartoma. Multidisciplinary team discussion is crucial in the management of atypical cases to ensure radiological-pathological concordance.

错构瘤是一种可见于不同器官的良性肿块,包括乳房。这些肿块定义明确,有假包膜和周围器官的可变组织。它是一种罕见的乳腺良性病变,其病因和发病机制尚不完全清楚。该肿瘤以女性为主,平均年龄为45岁。病例描述:我们报告两例乳房错构瘤在51岁和61岁的女性谁提出了我们通过筛查和症状诊所。这两个病例都有错构瘤诊断的典型影像学表现,但错构瘤内部存在扭曲,这增加了恶性肿瘤的可能性,并促使核心活检和MDT的讨论。实际意义:许多错构瘤具有典型的良性影像学表现,无需进一步研究。非典型错构瘤需要活检,以排除乳腺癌,虽然罕见,但可能在错构瘤内发展。多学科小组讨论在非典型病例的管理中至关重要,以确保影像学和病理学的一致性。
{"title":"Breast Hamartoma with Unusual Imaging Features.","authors":"Palwasha Gul, Jonathan James, Mohamad Hajaj, Dima AlNajjar","doi":"10.2478/jcas-2025-0005","DOIUrl":"10.2478/jcas-2025-0005","url":null,"abstract":"<p><strong>Introduction: </strong>Hamartomas are benign masses seen in different organs including breasts. These are well-defined masses with a pseudocapsule and variable tissues from the surrounding organ.It is an uncommonly reported benign breast lesion, the cause and pathogenesis of its development is still not fully understood. The tumour exhibits a female predominance with a mean age of 45.</p><p><strong>Case description: </strong>We present two cases of breast hamartoma in 51 and 61 years old female who presented to us through screening and symptomatic clinics.Both cases had imaging findings typical for diagnosis of hamartoma however there was a distortion within the hamartoma which raised possibility of malignancy and prompted a core biopsy and MDT discussion.</p><p><strong>Practical implication: </strong>Many hamartomas have typical benign imaging appearances and require no further investigation. Biopsy is needed in atypical looking hamartomas to exclude a breast carcinoma, which although rare may develop within a hamartoma. Multidisciplinary team discussion is crucial in the management of atypical cases to ensure radiological-pathological concordance.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"29-33"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer in Balochistan, Pakistan, 2020-2022: A Descriptive Study. 2020-2022年巴基斯坦俾路支省癌症:一项描述性研究。
Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0003
Farhana Badar, Shahid Mahmood, Omar Rasheed Chughtai, Muhammad Sohaib

Introduction: Between 2020 and 2022, Pakistan's population reached 235.7 million, with an average of 120.6 million men and 115.1 million women each year. Balochistan is in the southwest of Pakistan and is the fourth most populous region in the country, with an average annual population estimated at 13.9 m. There were 6.8 m (48.7%) children, 1.4 m (10.3%) adolescents, and 5.7 m (40.9%) adults over 2020-2022. The male population (7.4 m (52.6%)) was higher than the female population (6.6 m (47.4%)).

Materials and methods: We conducted a study from 2020 to 2022, retrospectively evaluating the distribution of cancer in Balochistan on data reported by the collaborating centers, namely, the Pakistan Atomic Energy Commission, Shaukat Khanum Memorial Cancer Hospital and Research Center, and Chughtai Lab. We computed the proportional distributions of the commonly diagnosed cancers by age category.

Results: We recorded 6,492 malignancies from Balochistan over three years from 2020 to 2022. In children (n=214 (3.3%)), 20.1% were Hodgkin lymphomas; in adolescents (n=214 (3.3%)), 19.6% were non-Hodgkin lymphomas (NHL); and in adults (n=6,064 (93.4%)), 17.5% were tumors of the breast.

Conclusion: This is the first report on regional cancer registration in the country's neglected province of Balochistan. It shows that cancer counts were low from 2020 to 2022. However, we can use the information recorded as the foundation to evaluate the statistics over time to see if any changes are recorded. We also need to increase awareness among the stakeholders about the impact of cancer surveillance in the region.

导读:2020年至2022年,巴基斯坦人口将达到2.357亿,平均每年男性为1.206亿,女性为1.151亿。俾路支省位于巴基斯坦西南部,是该国人口第四多的地区,年平均人口估计为1390万。在2020-2022年期间,有680万儿童(48.7%)、140万青少年(10.3%)和570万成年人(40.9%)。男性人口740万(52.6%)高于女性人口660万(47.4%)。材料和方法:我们从2020年到2022年进行了一项研究,根据巴基斯坦原子能委员会、Shaukat Khanum纪念癌症医院和研究中心、Chughtai实验室等合作中心报告的数据,回顾性评估了俾路支省的癌症分布。我们按年龄分类计算了常见癌症的比例分布。结果:从2020年到2022年,我们在俾路支省记录了6492例恶性肿瘤。在儿童中(n=214(3.3%)), 20.1%为霍奇金淋巴瘤;在青少年中(n=214(3.3%)), 19.6%为非霍奇金淋巴瘤(NHL);在成人(n= 6064(93.4%))中,17.5%为乳腺肿瘤。结论:这是巴基斯坦被忽视的俾路支省的第一份区域性癌症登记报告。报告显示,从2020年到2022年,癌症发病率很低。但是,我们可以使用记录的信息作为评估随时间推移的统计信息的基础,以查看是否记录了任何更改。我们还需要提高利益攸关方对该地区癌症监测影响的认识。
{"title":"Cancer in Balochistan, Pakistan, 2020-2022: A Descriptive Study.","authors":"Farhana Badar, Shahid Mahmood, Omar Rasheed Chughtai, Muhammad Sohaib","doi":"10.2478/jcas-2025-0003","DOIUrl":"10.2478/jcas-2025-0003","url":null,"abstract":"<p><strong>Introduction: </strong>Between 2020 and 2022, Pakistan's population reached 235.7 million, with an average of 120.6 million men and 115.1 million women each year. Balochistan is in the southwest of Pakistan and is the fourth most populous region in the country, with an average annual population estimated at 13.9 m. There were 6.8 m (48.7%) children, 1.4 m (10.3%) adolescents, and 5.7 m (40.9%) adults over 2020-2022. The male population (7.4 m (52.6%)) was higher than the female population (6.6 m (47.4%)).</p><p><strong>Materials and methods: </strong>We conducted a study from 2020 to 2022, retrospectively evaluating the distribution of cancer in Balochistan on data reported by the collaborating centers, namely, the Pakistan Atomic Energy Commission, Shaukat Khanum Memorial Cancer Hospital and Research Center, and Chughtai Lab. We computed the proportional distributions of the commonly diagnosed cancers by age category.</p><p><strong>Results: </strong>We recorded 6,492 malignancies from Balochistan over three years from 2020 to 2022. In children (n=214 (3.3%)), 20.1% were Hodgkin lymphomas; in adolescents (n=214 (3.3%)), 19.6% were non-Hodgkin lymphomas (NHL); and in adults (n=6,064 (93.4%)), 17.5% were tumors of the breast.</p><p><strong>Conclusion: </strong>This is the first report on regional cancer registration in the country's neglected province of Balochistan. It shows that cancer counts were low from 2020 to 2022. However, we can use the information recorded as the foundation to evaluate the statistics over time to see if any changes are recorded. We also need to increase awareness among the stakeholders about the impact of cancer surveillance in the region.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"12-16"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of patients with Acute Myeloid Leukemia receiving venetoclax in combination with azacitidine: A single center retrospective study from Pakistan. 急性髓系白血病患者接受venetoclax联合阿扎胞苷治疗的结果:一项来自巴基斯坦的单中心回顾性研究。
Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0001
Junaid Alam, Lavita Kumari, Usman Shaikh, Akbar Khan Muhammad Ali

Introduction: Acute Myeloid Leukemia (AML) has a peak incidence in elderly patients with the median age of onset being 68 years. Owing to the advanced age and multiple comorbidities, such patients are not candidates for the standard chemotherapeutic protocols. Here we discuss the treatment strategies employed for newly diagnosed elderly patients with AML at our institution and their associated outcomes.

Materials and methods: We conducted a single institutional retrospective review of cases which included elderly patients aged ≥ 50 years diagnosed with AML and treated with venetolcax in combination with azacitidine. Data relating to patients' characteristics, cytogenetics, molecular aberrations and vital status were extracted. We evaluated the overall survival (OS) as our primary outcome of interest.

Results: This study involved 58 patients with confirmed AML, with a median age of 61.5 years. The majority of patients were male (77.6%). Most patients (75.9%) died, while 15.5% were still under treatment at the end of the study period. The median OS was 7.0 months. There was no significant difference in survival based on comorbid conditions (p = 0.586). However, survival differed by gender, with a median OS of 6 months for males and 16 months for females (p = 0.021). The number of chemotherapy cycles significantly impacted survival, with increased cycles associated with a reduced hazard of death (HR = 0.74, p < 0.01).

Conclusion: Our findings contribute to the growing evidence that venetoclax combined with azacitidine is an effective treatment option for elderly patients with AML who are not eligible for intensive treatment.

急性髓系白血病(AML)在老年患者中发病率最高,中位发病年龄为68岁。由于高龄和多重合并症,这些患者不适合标准的化疗方案。在这里,我们讨论了在我们机构新诊断的老年AML患者的治疗策略及其相关结果。材料和方法:我们进行了一项单一机构回顾性研究,纳入了年龄≥50岁的诊断为急性髓性白血病(AML)的老年患者,并使用维奈托卡西联合阿扎胞苷治疗。提取与患者特征、细胞遗传学、分子畸变和生命状态有关的数据。我们评估总生存期(OS)作为我们感兴趣的主要结局。结果:本研究纳入了58例确诊AML患者,中位年龄为61.5岁。患者以男性居多(77.6%)。大多数患者(75.9%)死亡,而15.5%的患者在研究结束时仍在接受治疗。中位OS为7.0个月。两组共病生存率差异无统计学意义(p = 0.586)。然而,生存期因性别而异,男性的中位生存期为6个月,女性为16个月(p = 0.021)。化疗周期数显著影响生存,周期增加与死亡风险降低相关(HR = 0.74, p < 0.01)。结论:我们的研究结果提供了越来越多的证据,表明venetoclax联合阿扎胞苷是不符合强化治疗条件的老年AML患者的有效治疗选择。
{"title":"Outcomes of patients with Acute Myeloid Leukemia receiving venetoclax in combination with azacitidine: A single center retrospective study from Pakistan.","authors":"Junaid Alam, Lavita Kumari, Usman Shaikh, Akbar Khan Muhammad Ali","doi":"10.2478/jcas-2025-0001","DOIUrl":"10.2478/jcas-2025-0001","url":null,"abstract":"<p><strong>Introduction: </strong>Acute Myeloid Leukemia (AML) has a peak incidence in elderly patients with the median age of onset being 68 years. Owing to the advanced age and multiple comorbidities, such patients are not candidates for the standard chemotherapeutic protocols. Here we discuss the treatment strategies employed for newly diagnosed elderly patients with AML at our institution and their associated outcomes.</p><p><strong>Materials and methods: </strong>We conducted a single institutional retrospective review of cases which included elderly patients aged ≥ 50 years diagnosed with AML and treated with venetolcax in combination with azacitidine. Data relating to patients' characteristics, cytogenetics, molecular aberrations and vital status were extracted. We evaluated the overall survival (OS) as our primary outcome of interest.</p><p><strong>Results: </strong>This study involved 58 patients with confirmed AML, with a median age of 61.5 years. The majority of patients were male (77.6%). Most patients (75.9%) died, while 15.5% were still under treatment at the end of the study period. The median OS was 7.0 months. There was no significant difference in survival based on comorbid conditions (p = 0.586). However, survival differed by gender, with a median OS of 6 months for males and 16 months for females (p = 0.021). The number of chemotherapy cycles significantly impacted survival, with increased cycles associated with a reduced hazard of death (HR = 0.74, p < 0.01).</p><p><strong>Conclusion: </strong>Our findings contribute to the growing evidence that venetoclax combined with azacitidine is an effective treatment option for elderly patients with AML who are not eligible for intensive treatment.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Farewell to Arms - An Institutional Review of Conventional Staging for Intermediate-Risk Prostate Cancer. 告别武器——对中危前列腺癌常规分期的制度回顾。
Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0006
Rustam Karanjia, Pallab Sarkar, Vishnu Basavaraju, Oluwabunmi Tayo, Sashi Kommu, Humayun Bashir, Edward Streeter

Background: EAU guidelines advise patients with intermediate risk Gleason 4+3=7 prostate cancer undergo cross-sectional abdominopelvic imaging and bone scan for metastatic screening. We hypothesised detection rate of extra-prostatic disease in this cohort is low using conventional CT/bone scans and could potentially be avoided.

Materials and methods: Patients with overall Gleason 4+3 histology were identified over 69 months at East Kent University Hospitals NHS Trust. Patients were excluded if PSA >20ng/mL and/or MRI prostate >T3b stage. Primary outcomes were: (a) detection rates of metastatic disease using conventional CT and bone scan and b) the proportion of fully-staged patients with positive lymph nodes at dissection or biochemical recurrence following robotic-assisted laparoscopic prostatectomy (RALP).

Results: A total of 134 patients were identified. Median age was 72 (range 45-83), PSA 7.8ng/mL (range 1.8-19.3) and prostate volume 40cc (range 10-129). 130/134(97%) had MRI scans prior to staging. 124/134(93%) had bone scans and 83/134(62%) had CT scans, of which 77/134(57%) had both. 0/124(0%) bone scans identified metastatic disease and only 2/83(2%) CT scans identified nodal disease not detected by MRI. 0/134(0%) had management changes from staging. 57/134(43%) patients negatively-staged proceeded to RALP. 19/57(32%) had lymph node dissections. 6(11%) had missed metastatic disease at 19 months median follow-up.

Conclusion: Detection of metastatic disease by conventional CT and bone scan was poor in this cohort, despite their presence, and their recommendation by EAU seems unwarranted. Patients could safely avoid these scans and proceed directly to radical treatment, due to the theoretical benefit of treating despite oligometastatic disease.

背景:EAU指南建议中度风险Gleason 4+3=7前列腺癌患者接受横断面骨盆成像和骨扫描进行转移筛查。我们假设在该队列中使用常规CT/骨扫描前列腺外疾病的检出率很低,并且可能被避免。材料和方法:在东肯特大学医院NHS信托医院进行为期69个月的Gleason 4+3总体组织学鉴定。如果PSA bbb20 ng/mL和/或MRI前列腺>T3b分期,则排除患者。主要结局是:(a)常规CT和骨扫描对转移性疾病的检出率;(b)机器人辅助腹腔镜前列腺切除术(RALP)后淋巴结清扫阳性或生化复发的全分期患者比例。结果:共发现134例患者。中位年龄72岁(范围45-83),PSA 7.8ng/mL(范围1.8-19.3),前列腺体积40cc(范围10-129)。130/134(97%)患者在分期前进行了MRI扫描。124/134(93%)有骨扫描,83/134(62%)有CT扫描,其中77/134(57%)两者都有。0/124(0%)的骨扫描发现了转移性疾病,只有2/83(2%)的CT扫描发现了MRI未发现的结节性疾病。0/134(0%)从分期开始有管理变更。134例患者中有57例(43%)呈阴性阶段进入RALP。19/57(32%)有淋巴结清扫。6例(11%)在19个月的中位随访中未发现转移性疾病。结论:在该队列中,尽管存在转移性疾病,但常规CT和骨扫描检测转移性疾病的能力较差,EAU的推荐似乎是没有根据的。患者可以安全地避免这些扫描,并直接进行根治性治疗,这是由于尽管有少转移性疾病也可以治疗的理论益处。
{"title":"A Farewell to Arms - An Institutional Review of Conventional Staging for Intermediate-Risk Prostate Cancer.","authors":"Rustam Karanjia, Pallab Sarkar, Vishnu Basavaraju, Oluwabunmi Tayo, Sashi Kommu, Humayun Bashir, Edward Streeter","doi":"10.2478/jcas-2025-0006","DOIUrl":"10.2478/jcas-2025-0006","url":null,"abstract":"<p><strong>Background: </strong>EAU guidelines advise patients with intermediate risk Gleason 4+3=7 prostate cancer undergo cross-sectional abdominopelvic imaging and bone scan for metastatic screening. We hypothesised detection rate of extra-prostatic disease in this cohort is low using conventional CT/bone scans and could potentially be avoided.</p><p><strong>Materials and methods: </strong>Patients with overall Gleason 4+3 histology were identified over 69 months at East Kent University Hospitals NHS Trust. Patients were excluded if PSA >20ng/mL and/or MRI prostate >T3b stage. Primary outcomes were: (a) detection rates of metastatic disease using conventional CT and bone scan and b) the proportion of fully-staged patients with positive lymph nodes at dissection or biochemical recurrence following robotic-assisted laparoscopic prostatectomy (RALP).</p><p><strong>Results: </strong>A total of 134 patients were identified. Median age was 72 (range 45-83), PSA 7.8ng/mL (range 1.8-19.3) and prostate volume 40cc (range 10-129). 130/134(97%) had MRI scans prior to staging. 124/134(93%) had bone scans and 83/134(62%) had CT scans, of which 77/134(57%) had both. 0/124(0%) bone scans identified metastatic disease and only 2/83(2%) CT scans identified nodal disease not detected by MRI. 0/134(0%) had management changes from staging. 57/134(43%) patients negatively-staged proceeded to RALP. 19/57(32%) had lymph node dissections. 6(11%) had missed metastatic disease at 19 months median follow-up.</p><p><strong>Conclusion: </strong>Detection of metastatic disease by conventional CT and bone scan was poor in this cohort, despite their presence, and their recommendation by EAU seems unwarranted. Patients could safely avoid these scans and proceed directly to radical treatment, due to the theoretical benefit of treating despite oligometastatic disease.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"24-28"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond the Tumor: Invasive Fungal Infection Unveiled in HER2-Positive Breast Cancer Patient Mimicking Disease Relapse. 肿瘤之外:her2阳性乳腺癌患者模拟疾病复发的侵袭性真菌感染
Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0002
Maryam Imran, Muhammad Awais Majeed, Sameen-Bin-Naeem, Tahira Yasmeen, Neelam Siddiqui

Introduction: Breast cancer is a major global health concern among all malignancies, with HER2-positive breast cancer representing a particularly aggressive subtype. It affects approximately 20% of patients and is associated with a high risk of relapse. The management of HER2-positive breast cancer has been significantly improved by targeted therapies, though challenges remain, especially in resource-limited settings. Invasive fungal infections are also common and can manifest as metastatic lesions in immunocompromised cancer patients undergoing intensive treatments making the diagnosis challenging for the oncologists.

Case description: We report a case of a 39-year-old premenopausal female with relapsed HER2-positive breast cancer complicated by an invasive fungal infection. The patient initially presented with a 5 × 5 cm right breast lump, which was diagnosed as invasive ductal carcinoma, HER2-positive estrogen and progesterone receptor negative. Despite receiving chemotherapy with doxorubicin, cyclophosphamide, paclitaxel in the neoadjuvant setting and breast conservation surgery, the patient experienced disease recurrence. She was then treated with modified radical mastectomy followed by adjuvant chemotherapy TCH (trastuzumab, carboplatin, and docetaxel) six cycles. After three cycles, she developed high-grade fevers, renal impairment, and altered mental status. Imaging initially suggested ongoing infective vs metastatic process in bilateral renal and CNS parenchyma, so biopsy was performed from brain that revealed Aspergillus flavus infection. Treatment was adjusted to include antifungal therapy with voriconazole, and the patient's condition improved.

Practical implications: This case underscores the critical need for biopsy of new or evolving lesions in cancer patients, particularly when imaging is not convincing enough for a relapse. Accurate diagnosis is essential to differentiate between disease progression and complications such as opportunistic infections. The occurrence of a fungal brain abscess in this patient highlights the importance of considering such invasive opportunistic infections in immunocompromised individuals, especially those undergoing intensive chemotherapy. Furthermore, the challenges faced due to the unavailability of targeted therapies in resource-limited settings emphasize the need for better access to advanced treatments and comprehensive management strategies. This case also calls for heightened vigilance and prompt diagnostic evaluation to address both cancer progression and potential opportunistic infections effectively.

在所有恶性肿瘤中,乳腺癌是一个主要的全球健康问题,her2阳性乳腺癌是一种特别具有侵袭性的亚型。它影响了大约20%的患者,并且与复发的高风险相关。靶向治疗已经显著改善了her2阳性乳腺癌的管理,尽管挑战仍然存在,特别是在资源有限的环境中。侵袭性真菌感染也很常见,在接受强化治疗的免疫功能低下的癌症患者中表现为转移性病变,这对肿瘤学家来说是一个挑战。病例描述:我们报告一例39岁绝经前女性复发her2阳性乳腺癌合并侵袭性真菌感染。患者最初表现为右乳5 × 5 cm肿块,诊断为浸润性导管癌,her2阳性,雌激素和孕激素受体阴性。尽管在新辅助治疗中接受了阿霉素、环磷酰胺、紫杉醇的化疗和乳房保护手术,患者仍经历了疾病复发。然后,她接受改良根治性乳房切除术,随后辅助化疗TCH(曲妥珠单抗、卡铂和多西紫杉醇)6个周期。三个周期后,患者出现高热、肾功能损害和精神状态改变。最初的影像显示双侧肾脏和中枢神经系统实质存在持续的感染和转移过程,因此在脑部进行活检发现黄曲霉感染。治疗调整为伏立康唑抗真菌治疗,患者病情得到改善。实际意义:本病例强调了对癌症患者新发或发展中的病变进行活检的迫切需要,特别是当影像学检查不足以令人信服时。准确诊断对于区分疾病进展和并发症(如机会性感染)至关重要。该患者出现真菌性脑脓肿,强调了免疫功能低下个体,特别是接受强化化疗的个体,考虑这种侵袭性机会性感染的重要性。此外,由于在资源有限的环境中无法获得靶向治疗而面临的挑战强调需要更好地获得先进治疗和综合管理战略。这种情况也需要提高警惕和及时的诊断评估,以有效地解决癌症进展和潜在的机会性感染。
{"title":"Beyond the Tumor: Invasive Fungal Infection Unveiled in HER2-Positive Breast Cancer Patient Mimicking Disease Relapse.","authors":"Maryam Imran, Muhammad Awais Majeed, Sameen-Bin-Naeem, Tahira Yasmeen, Neelam Siddiqui","doi":"10.2478/jcas-2025-0002","DOIUrl":"10.2478/jcas-2025-0002","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is a major global health concern among all malignancies, with HER2-positive breast cancer representing a particularly aggressive subtype. It affects approximately 20% of patients and is associated with a high risk of relapse. The management of HER2-positive breast cancer has been significantly improved by targeted therapies, though challenges remain, especially in resource-limited settings. Invasive fungal infections are also common and can manifest as metastatic lesions in immunocompromised cancer patients undergoing intensive treatments making the diagnosis challenging for the oncologists.</p><p><strong>Case description: </strong>We report a case of a 39-year-old premenopausal female with relapsed HER2-positive breast cancer complicated by an invasive fungal infection. The patient initially presented with a 5 × 5 cm right breast lump, which was diagnosed as invasive ductal carcinoma, HER2-positive estrogen and progesterone receptor negative. Despite receiving chemotherapy with doxorubicin, cyclophosphamide, paclitaxel in the neoadjuvant setting and breast conservation surgery, the patient experienced disease recurrence. She was then treated with modified radical mastectomy followed by adjuvant chemotherapy TCH (trastuzumab, carboplatin, and docetaxel) six cycles. After three cycles, she developed high-grade fevers, renal impairment, and altered mental status. Imaging initially suggested ongoing infective vs metastatic process in bilateral renal and CNS parenchyma, so biopsy was performed from brain that revealed Aspergillus flavus infection. Treatment was adjusted to include antifungal therapy with voriconazole, and the patient's condition improved.</p><p><strong>Practical implications: </strong>This case underscores the critical need for biopsy of new or evolving lesions in cancer patients, particularly when imaging is not convincing enough for a relapse. Accurate diagnosis is essential to differentiate between disease progression and complications such as opportunistic infections. The occurrence of a fungal brain abscess in this patient highlights the importance of considering such invasive opportunistic infections in immunocompromised individuals, especially those undergoing intensive chemotherapy. Furthermore, the challenges faced due to the unavailability of targeted therapies in resource-limited settings emphasize the need for better access to advanced treatments and comprehensive management strategies. This case also calls for heightened vigilance and prompt diagnostic evaluation to address both cancer progression and potential opportunistic infections effectively.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"8-11"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urdu Translation and Validation of the COST-FACIT Tool for Assessing Financial Toxicity Among Patients Diagnosed with Cancer in Pakistan. 乌尔都语翻译和验证成本-事实工具评估在巴基斯坦诊断为癌症的患者的财务毒性。
Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI: 10.2478/jcas-2025-0004
Muhammad Tayyab Ul Hasan Siddiqui, Sehar Salim Virani, Fatima Shaukat, Asfia Arham Khursheed, Lubna Saleem, Abid Jamal, Muhammad Rizwan Khan, Syed Nabeel Zafar

Introduction: Cancer treatment can impose a significant financial burden on patients, impacting their quality of life. The COST-FACIT tool is commonly used to assess financial toxicity (FT) in cancer patients. This study aimed to translate and validate an Urdu version of the COST-FACIT tool in Pakistan.

Materials and methods: A cross-sectional validation study was conducted at four tertiary care hospitals in Karachi, Pakistan, from October to December 2023. We translated and back-translated the 12-item COST-FACIT tool and validated it in accordance with FACIT guidelines. The study included 10 native Urdu-speaking cancer patients as recommended in the guidelines. The analysis included descriptive statistics, content validity indices, and assessment of internal consistency using Cronbach's alpha, analyzed with Stata MP v.14 software.

Results: The study population included 6 females (60%) and 4 males (40%), with most participants aged between 40 and 60 years (4 patients, 40%). The mean FACIT COST score was 16.3 (SD = 11.255, range 4-40), with 6 (60%) patients experiencing moderate (Grade 2) financial toxicity. Internal consistency was good, with a Cronbach's alpha of 0.90, and content validity indices indicated items were relevant and clear (average expert CVI = 0.82 for relevance, 0.90 for clarity).

Conclusion: We have translated and validated an Urdu version of the COST-FACIT tool. It is a valid and reliable instrument to assess financial toxicity experienced by cancer patients in Pakistan.

导读:癌症治疗会给患者带来巨大的经济负担,影响他们的生活质量。成本- facit工具通常用于评估癌症患者的财务毒性(FT)。本研究的目的是在巴基斯坦翻译和验证成本- facit工具的乌尔都语版本。材料和方法:于2023年10月至12月在巴基斯坦卡拉奇的四家三级保健医院进行了一项横断面验证研究。我们翻译和反翻译了12项成本-FACIT工具,并根据FACIT指南对其进行了验证。该研究纳入了指南中推荐的10名母语为乌尔都语的癌症患者。分析包括描述性统计、内容效度指标和内部一致性评估,使用Stata MP v.14软件进行分析。结果:研究人群中女性6例(60%),男性4例(40%),年龄以40 ~ 60岁为主(4例,40%)。平均FACIT COST评分为16.3 (SD = 11.255,范围4-40),6例(60%)患者出现中度(2级)财务毒性。内部一致性良好,Cronbach's alpha为0.90,内容效度指标表明项目相关且清晰(专家平均CVI = 0.82相关性,0.90清晰度)。结论:我们已经翻译并验证了一个乌尔都语版本的COST-FACIT工具。这是一个有效和可靠的工具来评估巴基斯坦癌症患者所经历的财务毒性。
{"title":"Urdu Translation and Validation of the COST-FACIT Tool for Assessing Financial Toxicity Among Patients Diagnosed with Cancer in Pakistan.","authors":"Muhammad Tayyab Ul Hasan Siddiqui, Sehar Salim Virani, Fatima Shaukat, Asfia Arham Khursheed, Lubna Saleem, Abid Jamal, Muhammad Rizwan Khan, Syed Nabeel Zafar","doi":"10.2478/jcas-2025-0004","DOIUrl":"10.2478/jcas-2025-0004","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer treatment can impose a significant financial burden on patients, impacting their quality of life. The COST-FACIT tool is commonly used to assess financial toxicity (FT) in cancer patients. This study aimed to translate and validate an Urdu version of the COST-FACIT tool in Pakistan.</p><p><strong>Materials and methods: </strong>A cross-sectional validation study was conducted at four tertiary care hospitals in Karachi, Pakistan, from October to December 2023. We translated and back-translated the 12-item COST-FACIT tool and validated it in accordance with FACIT guidelines. The study included 10 native Urdu-speaking cancer patients as recommended in the guidelines. The analysis included descriptive statistics, content validity indices, and assessment of internal consistency using Cronbach's alpha, analyzed with Stata MP v.14 software.</p><p><strong>Results: </strong>The study population included 6 females (60%) and 4 males (40%), with most participants aged between 40 and 60 years (4 patients, 40%). The mean FACIT COST score was 16.3 (SD = 11.255, range 4-40), with 6 (60%) patients experiencing moderate (Grade 2) financial toxicity. Internal consistency was good, with a Cronbach's alpha of 0.90, and content validity indices indicated items were relevant and clear (average expert CVI = 0.82 for relevance, 0.90 for clarity).</p><p><strong>Conclusion: </strong>We have translated and validated an Urdu version of the COST-FACIT tool. It is a valid and reliable instrument to assess financial toxicity experienced by cancer patients in Pakistan.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"11 1","pages":"17-23"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of cancer & allied specialties
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1